Saniona Past Earnings Performance

Past criteria checks 0/6

Saniona's earnings have been declining at an average annual rate of -24.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 26.4% per year.

Key information

-24.8%

Earnings growth rate

-10.1%

EPS growth rate

Biotechs Industry Growth	0.7%
Revenue growth rate	-26.4%
Return on equity	n/a
Net Margin	-568.9%
Next Earnings Update	30 Apr 2024

Recent past performance updates

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

Revenue & Expenses Breakdown
Beta

How Saniona makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:SANION Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	17	-96	81
30 Sep 23	15	-108	52
30 Jun 23	12	-66	9
31 Mar 23	11	-134	78
31 Dec 22	15	-245	194
30 Sep 22	15	-334	330
30 Jun 22	15	-445	439
31 Mar 22	14	-461	450
31 Dec 21	10	-411	409
30 Sep 21	9	-326	352
30 Jun 21	9	-280	300
31 Mar 21	9	-200	225
31 Dec 20	8	-73	160
30 Sep 20	11	-25	113
30 Jun 20	9	-5	102
31 Mar 20	8	-1	95
31 Dec 19	7	-69	95
30 Sep 19	5	-96	110
30 Jun 19	49	-53	108
31 Mar 19	52	-52	115
31 Dec 18	55	-41	104
30 Sep 18	57	-32	89
30 Jun 18	17	-61	85
31 Mar 18	17	-56	79
31 Dec 17	21	-49	74
30 Sep 17	21	-47	74
30 Jun 17	68	-6	71
31 Mar 17	67	-2	67
31 Dec 16	75	2	69
30 Sep 16	71	10	56
30 Jun 16	23	-25	52
31 Mar 16	25	-21	46
31 Dec 15	14	-23	39
30 Sep 15	16	-23	41
30 Jun 15	19	-16	36
31 Mar 15	23	-10	33
31 Dec 14	22	-6	27
31 Dec 13	13	-1	14

Quality Earnings: SANION is currently unprofitable.

Growing Profit Margin: SANION is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SANION is unprofitable, and losses have increased over the past 5 years at a rate of 24.8% per year.

Accelerating Growth: Unable to compare SANION's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SANION is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).

Return on Equity

High ROE: SANION's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Saniona Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Recent updates

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - kr42.50

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - kr29.30

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Revenue & Expenses Breakdown
Beta